[Temporary Announcement] Deyuan Pharmaceutical: Announcement that Allopurinol Tablets have been issued a drug registration certificate by the State Food and Drug Administration
Securities code: 920735 Securities abbreviation: Deyuan Pharmaceutical Announcement number: 2025-116
Jiangsu Deyuan Pharmaceutical Co., Ltd.
Announcement on Allopurinol Tablets being issued a Drug Registration Certificate by the State Food and Drug Administration
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
On December 9, 2025, Jiangsu Deyuan Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received a drug registration certificate approved and issued by the National Medical Products Administration (NMPA) for its allopurinol tablets filed under Category 3 chemical drugs, and was deemed to have passed the consistency evaluation.
1. Basic information on drugs
- Drug name: Allopurinol tablets
Dosage form: tablet
Specifications: 0.1g
Registration classification: Chemical drugs Class 3
Approval number: National Drug Approval No. H20256109
Pharmaceutical manufacturer: Jiangsu Deyuan Pharmaceutical Co., Ltd.
- Other situations of drugs
Allopurinol is indicated for the treatment of primary or secondary gout. Allopurinol acts on purine catabolism and does not interfere with purine biosynthesis. Allopurinol is a structural analog of the natural purine base hypoxanthine and a xanthine oxidase inhibitor. It reduces the production of uric acid by inhibiting xanthine oxidase.
Allopurinol tablets were launched in the United States in 1966 with the trade name: ZYLOPRIM; in 1969 in Japan with the trade name: Zyloric; in 1985 in China with the specification of 0.1g. This variety has been included in the national Class A medical
1/2
Guaranteed Drug Catalog (2024 Edition). As of now, 17 domestic generic companies have approval numbers, and 6 of them have passed or are deemed to have passed the consistency evaluation.
2. Impact on the company and risk warning
The approval of allopurinol tablets will further enrich the company's product line, optimize the product structure, improve the company's market competitiveness, and increase sales growth points.
After a drug obtains a registration certificate, there will be certain uncertainties in the production and sales of the product due to factors such as the market environment and national policies. Investors are kindly requested to make prudent decisions and pay attention to preventing investment risks.
3. Documents for reference
"Drug Registration Certificate" issued by the State Drug Administration.
Board of Directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. December 10, 2025
2/2